{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:18:24Z","timestamp":1792919904244,"version":"4.5.0"},"reference-count":31,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While the use of chimeric antigen receptor\u2010T (CAR\u2010T) therapy for T\u2010cell malignancies is in the early stage of clinical trials, it exhibits substantial potential to offer long\u2010term remission for patients with refractory\/relapsed (R\/R) T\u2010cell malignancies. In our phase I\/II clinical trials, 65 pediatric and adult patients with R\/R T\u2010cell acute lymphoblastic leukemia and lymphoblastic lymphoma (T\u2010ALL\/LBL) were enrolled (NCT04572308 and NCT04916860). Of these, 60 participants (T\u2010ALL 35, T\u2010LBL 25) received a single dose of naturally selected anti\u2010CD7 CAR (NS7CAR) T cells at three levels: a low dose (5\u2009\u00d7\u200910\n                    <jats:sup>5<\/jats:sup>\n                    \/kg), a medium dose (1 to 1.5\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg), and a high dose (2\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg). On day 28, 94.4% of patients achieved deep complete remission (CR) in bone marrow. Among the 32 patients with extramedullary disease, 78.1% showed response, with 56.3% in CR and 21.9% in partial remission. The 2\u2010year overall survival and progression\u2010free survival (PFS) were 63.5% (95% CI 47.7\u201379.4) and 53.7% (95% CI, 38.9\u201368.6), with no difference between pediatric and adult patients. PFS was significantly higher among the 37 CR patients who proceeded with consolidation transplant than the 10 patients who did not with 1\u2010year PFS 67.2% (95% CI 51.9\u201382.4) versus 15.0% (95% CI 0\u201340.2),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.0001. Of the 10 CR patients without transplants, eight relapsed, while two sustained CR on day 128, and day 180, respectively. Cytokine release syndrome occurred in 91.7% of patients (grade 1\/2 in 80.0%, grade 3\/4 in 11.7%) and 5% of patients had neurotoxicity. NS7CAR\u2010T therapy is effective in treating R\/R T\u2010ALL\/LBL patients with promising PFS while maintaining a manageable safety profile.\n                  <\/jats:p>","DOI":"10.1002\/ajh.27094","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T13:23:02Z","timestamp":1695475382000},"page":"1898-1908","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Analysis of 60 patients with relapsed or refractory T\u2010cell acute lymphoblastic leukemia and T\u2010cell lymphoblastic lymphoma treated with\n                    <scp>CD7<\/scp>\n                    \u2010targeted chimeric antigen receptor\u2010T cell therapy"],"prefix":"10.1002","volume":"98","author":[{"given":"Xian","family":"Zhang","sequence":"first","affiliation":[{"name":"Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Yang","sequence":"additional","affiliation":[{"name":"Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[{"name":"Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Qiu","sequence":"additional","affiliation":[{"name":"Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[{"name":"Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan\u2010li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jin","sequence":"additional","affiliation":[{"name":"Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Li","sequence":"additional","affiliation":[{"name":"Hebei Senlang Biotechnology Co., Ltd.  Shijiazhuang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-7369","authenticated-orcid":false,"given":"Peihua","family":"Lu","sequence":"additional","affiliation":[{"name":"Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9,23]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009928"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.2.517"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.12.5749"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/9.12.1875"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149819"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201021\u20104097"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.02.013"},{"issue":"11","key":"e_1_2_10_10_1","first-page":"5263","article-title":"Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7\u2010positive malignancies","volume":"11","author":"Chen D","year":"2021","journal-title":"Am J Cancer Res"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.09.003"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100065\u20105"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00389"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010019\u20100051\u20102"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014498"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015020"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422\u2010022\u201000721\u2010y"},{"key":"e_1_2_10_18_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Version 2.2019 Acute Lymphoblastic Leukemia.2019.https:\/\/www.nccn.org"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_10_20_1","unstructured":"U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES.Common Terminology Criteria for Adverse Events (CTCAE)Version 5.0. CI Cancer Therapy Evaluation Program (CTEP).2017.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed March 29 2021"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009098"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01222\u20108"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018\u2010011\u20100798\u2010z"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2278"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2010021\u201003009\u2010z"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010022\u201001756\u2010w"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061501"},{"key":"e_1_2_10_28_1","volume-title":"TECARTUS (brexucabtagene autoleucel), package insert","author":"US Food and Drug Administration","year":"2022"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.56875\/2589\u20100646.1047"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003618"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010022\u201000694\u20106"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001463"}],"updated-by":[{"DOI":"10.1002\/ajh.27217","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000}}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.27094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T05:08:01Z","timestamp":1711688881000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,23]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/ajh.27094"],"URL":"https:\/\/doi.org\/10.1002\/ajh.27094","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,23]]},"assertion":[{"value":"2023-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}